文献速递消化、代谢与肾脏急症

Eplontersen治疗伴多发性神经病的遗传性转甲状腺素蛋白淀粉样变性

Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy.
PubMed 文献 · JAMA · 2023-01-01
一句话结论在ATTRv多发性神经病患者中,与历史安慰剂相比,依普隆特生(eplontersen)显著降低血清转甲状腺素蛋白浓度、减轻神经损伤并改善生活质量。

NEURO-TTRansform是一项开放标签、单组、3期试验,在15个国家40个中心纳入168例Coutinho 1或2期ATTRv多发性神经病成人患者,其中144例接受皮下依普隆特生45 mg每4周一次,24例接受皮下因奥替生(inotersen)300 mg每周一次作为小参考组;历史安慰剂组为NEURO-TTR试验中60例接受安慰剂的患者。第65周,依普隆特生组血清转甲状腺素蛋白浓度调整后平均降低81.7%,安慰剂组降低11.2%(差值-70.4%[95%CI -75.2%至-65.7%],P<.001)。第66周,mNIS+7复合评分变化依普隆特生组0.3 vs 安慰剂组25.1(差值-24.8[95%CI -31.0至-18.6],P<.001),Norfolk QoL-DN总分变化-5.5 vs 14.2(差值-19.7[95%CI -25.6至-13.8],P<.001)。

要点

  • 第65周血清转甲状腺素蛋白浓度调整后平均降低:依普隆特生组81.7% vs 安慰剂组11.2%,差值-70.4%(95%CI -75.2%至-65.7%),P<.001。
  • 第66周mNIS+7复合评分变化:依普隆特生组0.3 vs 安慰剂组25.1,差值-24.8(95%CI -31.0至-18.6),P<.001,依普隆特生组神经功能损害更轻。
  • 第66周Norfolk QoL-DN总分变化:依普隆特生组-5.5 vs 安慰剂组14.2,差值-19.7(95%CI -25.6至-13.8),P<.001,依普隆特生组生活质量更优。
  • 截至第66周,因不良事件导致停药:依普隆特生组6例(4%)vs 安慰剂组2例(3%);依普隆特生组死亡2例(心脏心律失常、脑出血),安慰剂组无死亡。

适用人群与场景

  • 成人Coutinho 1或2期ATTRv多发性神经病患者,神经病变损害评分10-130,且有记录的TTR变异;共168例,来自15个国家40个中心。
  • 依普隆特生组144例(平均年龄53.0岁,男性69%),因奥替生参考组24例,历史安慰剂组60例(平均年龄59.5岁,男性68%)。

处置流程与药物剂量

  • 依普隆特生45 mg皮下注射,每4周一次(n=144)。
  • 因奥替生300 mg皮下注射,每周一次(小参考组,n=24)。
  • 历史安慰剂组接受皮下安慰剂每周一次(NEURO-TTR试验,n=60)。

研究设计与关键结果

  • NEURO-TTRansform为开放标签、单组、3期试验,2019年12月至2023年4月在15个国家40个中心纳入168例ATTRv多发性神经病成人患者;历史安慰剂组来自NEURO-TTR试验(NCT01737398;2013年3月至2017年11月)的60例安慰剂患者。
  • 主要疗效终点为第65/66周血清转甲状腺素蛋白浓度、mNIS+7复合评分(评分范围-22.3至346.3,分数越高功能越差)和Norfolk QoL-DN总分(评分范围-4至136,分数越高生活质量越差)较基线的变化;采用混合效应模型重复测量,以倾向评分加权校正。
  • 第65周血清转甲状腺素蛋白调整后平均降低:依普隆特生组81.7% vs 安慰剂组11.2%,差值-70.4%(95%CI -75.2%至-65.7%),P<.001。
  • 第66周mNIS+7复合评分较基线变化:依普隆特生组0.3 vs 安慰剂组25.1,差值-24.8(95%CI -31.0至-18.6),P<.001。
  • 第66周Norfolk QoL-DN总分较基线变化:依普隆特生组-5.5 vs 安慰剂组14.2,差值-19.7(95%CI -25.6至-13.8),P<.001。
  • 截至第66周,因不良事件导致停药:依普隆特生组6例(4%)vs 安慰剂组2例(3%);依普隆特生组死亡2例(心脏心律失常、脑出血),与已知疾病相关后遗症一致,安慰剂组无死亡。
  • 完成第66周随访:依普隆特生组136例(94.4%),安慰剂组52例(86.7%)。

证据类型、等级与局限

  • 证据类型:开放标签、单组、3期试验,使用历史安慰剂对照;主要疗效分析基于倾向评分加权的混合效应模型重复测量。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在ATTRv多发性神经病患者中,依普隆特生治疗组显示出与血清转甲状腺素蛋白浓度显著降低、神经病变损害更轻和生活质量更优一致的变化,对照为历史安慰剂。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Transthyretin gene silencing is an emerging treatment strategy for hereditary transthyretin (ATTRv) amyloidosis.

OBJECTIVE: To evaluate eplontersen, an investigational ligand-conjugated antisense oligonucleotide, in ATTRv polyneuropathy.

DESIGN, SETTING, AND PARTICIPANTS: NEURO-TTRansform was an open-label, single-group, phase 3 trial conducted at 40 sites across 15 countries (December 2019-April 2023) in 168 adults with Coutinho stage 1 or 2 ATTRv polyneuropathy, Neuropathy Impairment Score 10-130, and a documented TTR variant. Patients treated with placebo from NEURO-TTR (NCT01737398; March 2013-November 2017), an inotersen trial with similar eligibility criteria and end points, served as a historical placebo ("placebo") group.

INTERVENTIONS: Subcutaneous eplontersen (45 mg every 4 weeks; n = 144); a small reference group received subcutaneous inotersen (300 mg weekly; n = 24); subcutaneous placebo weekly (in NEURO-TTR; n = 60).

MAIN OUTCOMES AND MEASURES: Primary efficacy end points at week 65/66 were changes from baseline in serum transthyretin concentration, modified Neuropathy Impairment Score +7 (mNIS+7) composite score (scoring range, -22.3 to 346.3; higher scores indicate poorer function), and Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN) total score (scoring range, -4 to 136; higher scores indicate poorer quality of life). Analyses of efficacy end points were based on a mixed-effects model with repeated measures adjusted by propensity score weights.

RESULTS: Among 144 eplontersen-treated patients (mean age, 53.0 years; 69% male), 136 (94.4%) completed week-66 follow-up; among 60 placebo patients (mean age, 59.5 years; 68% male), 52 (86.7%) completed week-66 follow-up. At week 65, adjusted mean percentage reduction in serum transthyretin was -81.7% with eplontersen and -11.2% with placebo (difference, -70.4% [95% CI, -75.2% to -65.7%]; P < .001). Adjusted mean change from baseline to week 66 was lower (better) with eplontersen vs placebo for mNIS+7 composite score (0.3 vs 25.1; difference, -24.8 [95% CI, -31.0 to -18.6; P < .001) and for Norfolk QoL-DN (-5.5 vs 14.2; difference, -19.7 [95% CI, -25.6 to -13.8]; P < .001). Adverse events by week 66 that led to study drug discontinuation occurred in 6 patients (4%) in the eplontersen group vs 2 (3%) in the placebo group. Through week 66, there were 2 deaths in the eplontersen group consistent with known disease-related sequelae (cardiac arrhythmia; intracerebral hemorrhage); there were no deaths in the placebo group.

CONCLUSIONS AND RELEVANCE: In patients with ATTRv polyneuropathy, the eplontersen treatment group demonstrated changes consistent with significantly lowered serum transthyretin concentration, less neuropathy impairment, and better quality of life compared with a historical placebo.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04136184; EU Clinical Trials Register: EudraCT 2019-001698-10.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Coelho T, Marques W, Dasgupta NR, et al. Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy. JAMA. 2023. PMID: 37768671. doi:10.1001/jama.2023.18688

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。